Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

copper Cu 64-DOTA-trastuzumab

A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with the radioisotope copper Cu 64 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of copper Cu 64-DOTA-trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase and client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.
Synonym:64Cu-DOTA-trastuzumab
Search NCI's Drug Dictionary